Tilray Inc (NASDAQ:TLRY) – Investment analysts at Piper Jaffray Companies issued their FY2018 earnings per share estimates for shares of Tilray in a note issued to investors on Tuesday, January 8th. Piper Jaffray Companies analyst M. Lavery anticipates that the company will post earnings of ($0.79) per share for the year. Piper Jaffray Companies has a “Overweight” rating and a $90.00 price objective on the stock. Piper Jaffray Companies also issued estimates for Tilray’s Q4 2018 earnings at ($0.33) EPS, Q1 2019 earnings at ($0.43) EPS, Q2 2019 earnings at ($0.38) EPS, Q3 2019 earnings at ($0.32) EPS, Q4 2019 earnings at ($0.28) EPS, FY2019 earnings at ($1.40) EPS, Q1 2020 earnings at ($0.22) EPS, Q2 2020 earnings at ($0.19) EPS, Q3 2020 earnings at $0.01 EPS, Q4 2020 earnings at $0.21 EPS and FY2020 earnings at ($0.20) EPS.

Several other analysts also recently weighed in on TLRY. Roth Capital reiterated a “neutral” rating on shares of Tilray in a research note on Tuesday, October 2nd. Cowen upped their target price on Tilray from $62.00 to $172.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 9th. Benchmark assumed coverage on Tilray in a research note on Tuesday, October 16th. They issued a “buy” rating and a $200.00 target price on the stock. Finally, Zacks Investment Research downgraded Tilray from a “hold” rating to a “sell” rating in a research note on Tuesday, October 16th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Tilray currently has a consensus rating of “Buy” and an average target price of $124.25.

Tilray stock opened at $80.40 on Friday. The company has a current ratio of 5.43, a quick ratio of 4.98 and a debt-to-equity ratio of 0.05. Tilray has a fifty-two week low of $20.10 and a fifty-two week high of $300.00.

Tilray (NASDAQ:TLRY) last posted its quarterly earnings results on Tuesday, November 13th. The company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.08). The firm had revenue of $10.00 million for the quarter, compared to analysts’ expectations of $10.25 million. Tilray had a negative net margin of 121.22% and a negative return on equity of 60.74%. The company’s revenue was up 85.2% on a year-over-year basis.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Captrust Financial Advisors acquired a new position in Tilray in the 3rd quarter worth about $103,000. IFP Advisors Inc purchased a new position in Tilray in the third quarter valued at $154,000. G&S Capital LLC purchased a new position in Tilray in the third quarter valued at $155,000. Independent Advisor Alliance purchased a new position in Tilray in the third quarter valued at $216,000. Finally, Raging Capital Management LLC purchased a new position in Tilray in the third quarter valued at $215,000. 6.08% of the stock is owned by institutional investors.

Tilray Company Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.

Read More: What strategies should day traders use to execute a trade?

Earnings History and Estimates for Tilray (NASDAQ:TLRY)

Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.